Search

Start Over Journal or Parent Publication Title EJHaem

  • A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus.

    A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus.
    Authors:Christopher Dittus, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.Natalie Grover, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.Tarsheen Sethi, Yale University New Haven Connecticut USA.Jonathon Cohen, Emory UniversityAlfredo Voloschin, Emory UniversityJanhvi Rabadey, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.Xianming Tan, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.Anne Beaven, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.Steven I Park, Atrium Health Levine Cancer Institute Charlotte North Carolina USA.
    Date:2022
    Publisher:British Society for Haematology and John Wiley & Sons Ltd.
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

    Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.
    Authors:Paul G Richardson, Jerome Lipper Multiple Myeloma Center Department of Medical Oncology Dana-Farber Cancer Institute Harvard Medical School Boston Massachusetts.Sundar Jagannath, Mount Sinai Medical Center New York New York.Ajai Chari, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York.Dan T Vogl, Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania.Meletios A Dimopoulos, National and Kapodistrian University of Athens School of Medicine Athens Greece.Philippe Moreau, CHU de Nantes-Hôtel Dieu Nantes France.David Dingli, Mayo Clinic Rochester Minnesota.Lee-Jen Wei, Harvard T.H. Chan School of Public Health Boston Massachusetts.Joshua Richter, Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey.Noa Biran, Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey.David Siegel, Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey.William Reichmann, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Lingling Li, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Shijie Tang, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Jean-Ricjard Saint-Martin, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Anita Joshi, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Michael Kauffman, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Jatin Shah, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Sharon Shacham, Karyopharm Therapeutics Inc. Newton Massachusetts USA.Sagar Lonial, Emory University
    Date:2021
    Publisher:British Society for Haematology and John Wiley & Sons Ltd.
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study.

    Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study.
    Authors:Juan Li, Emory UniversityLorraine Cafuir, Emory UniversityManila Gaddh, Emory UniversityChristine Kempton, Emory University
    Date:2022
    Publisher:John Wiley & Sons, Inc
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial

    Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
    Authors:Noa Biran, Hackensack University Medical CenterBinod Dhakal, Medical College of WisconsinSuzanne Lentzsch, Columbia UniversityDavid Siegel, Hackensack University Medical CenterSaad Z Usmani, Levine Cancer InstituteAdriana Rossi, Weill Cornell MedicineCare Rosenbaum, Weill Cornell MedicineDivaya Bhutani, Columbia UniversityDavid H Vesole, Hackensack University Medical CenterCesar Rodriguez, Wake Forest Baptist Comprehensive Cancer CenterAjay Nooka, Emory UniversityFrits van Rhee, University of Arkansas of Medical SciencesLisette Stork-Sloots, Medex15Femke de Snoo, Medex15Pritish K Bhattacharyya, Hackensack University Medical CenterDurga Prasad Dash, Versiti Blood Center of WisconsinSena Zümrütçü, SkylineDxMartin H van Vliet, SkylineDxParameswaran Hari, Medical College of WisconsinRuben Niesvizky, Weill Cornell Medical Center
    Date:2021
    Publisher:John Wiley & Sons Ltd
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International